GRI Bio, Inc. (GRI) vs PharmaCyte Biotech, Inc. (PMCB)
Over the past 5 years, PMCB outperformed GRI — -33.59% vs -95.39% annualized total return (price plus dividends).
A side-by-side comparison of GRI Bio, Inc. and PharmaCyte Biotech, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
Total return — GRI vs PMCB
growth of $100 · dividends reinvested · last 6yMetrics side by side
Did PMCB beat GRI?
Over the past 5 years, PMCB outperformed GRI — -33.59% vs -95.39% annualized total return (price plus dividends).
Total return (annualized)
| Metric | GRI | PMCB |
|---|---|---|
| Total return (1Y) | -96.44% | -62.31% |
| Total return CAGR (3Y) | -97.04% | -42.38% |
| Total return CAGR (5Y) | -95.39% | -33.59% |
| Total return CAGR (10Y) | N/A | -39.91% |
GRI is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).
Frequently asked
- Has PMCB beaten GRI?
- Over the past 5 years, PMCB outperformed GRI — -33.59% vs -95.39% annualized total return (price plus dividends).
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.